We are a biopharmaceutical company dedicated to the research, development, production, and commercialization of innovative biological medicines based on the intestinal microbiota.

We are developing a new generation of biological drugs that offers solutions to serious diseases, which currently have no effective therapeutic alternatives, such as intestinal Clostridioides difficile
infection, non-alcoholic steatohepatitis, bacterial multi-resistance to antibiotics and certain types of metastatic cancers.

Our daily efforts are focused on introducing the first biological medicine based on intestinal microbiota: MBK-01, with FSPIM® (Full Spectrum Purified Intestinal Microbiota) technology, in an innovative lyophilized intestinal microbiota capsule format, to the European market.

  • Area of Activity
  • Digestive system
  • Microbiology
  • Pharmacy
  • Clinical trials
  • Rares diseases
  • Drug development
  • Cancer
  • Biodrugs
  • Company type
  • Health Biotechnology
Parque Tecnológico de Bizkaia C/ Astondo Bidea, 612
Derio, Vizcaya 48160, ES
P: 944540166

17 people. Everyone high qualifies professionals

Juan Basterra: CEO
More than 25 years of experience in the
Pharmaceutical Industry, the last 15 as Deputy Director at Faes Farma
MBA by Deusto Business School.
Medicine degree.

Celia Morales: Directora Técnica
Experience as Head of Quality Control in Cell Therapy for Osakidetza, and as Researcher at Praxis Pharmaceuticals and at the University of the Basque Country UPV/EHU, where she has managed during the last 3 years the transfer of biological samples.
PhD in Cell Biology and Pharmacy degree.

Patricia del Río: Directora de BD & Innovación
Experience as R&D Project Manager in different European companies, having worked in a microbiota company.
Extensive postdoctoral research.
PhD in Molecular Biology and Biomedicine and a Master’s degree in Cell Biology and Histology.

Leire Miñón: Directora Financiera

1.ICD-01: MBK-01, Oral capsules for Primary and Recurrent Clostridioides Difficile

2.NASH: MBK-01, Oral capsules for Nonalcoholic Steatohepatitis

3.CRE: MBK-01, Oral capsules for Carbapenem-resistant Enterobacteriaceace

4.Oncology Metastatic Cancer Program



Mikrobiomik will be the first company in the world to commercialize in the EU the first biological medicine based on gut microbiota in the innovative format of freeze-dried gut microbiota capsules, with FSPIM (Full Spectrum & Purified Intestinal Microbiota) technology.


We are pioneers in Europe in translating knowledge of the microbiota into completely innovative and non-invasive drugs that improve patients' quality of life.

We are currently in a pre-negotiation phase with several pharmaceutical companies to license and authorize them to commercialize our product MBK-01 for the indication of Clostridioides Difficile.

Mikrobiomik Healthcare Company